Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Discovery

• Publication date

  2012-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-11-0171PMID 22588881
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disclosure of Potential Conflicts of Interest

  2014cited by this paper
• TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.

  2011cited by this paper
• CD34+ Cells Represent Highly Functional Endothelial Progenitor Cells in Murine Bone Marrow

  2011cited by this paper
• Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.

  2011cited by this paper
• A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

  2010cited by this paper
• Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

  2009cited by this paper
• Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

  2009cited by this paper
• Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger.

  2009cited by this paper
• High Levels of Circulating VEGFR2+ Bone Marrow–Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies

  2009cited by this paper
• Quantification of circulating mature endothelial cells using a whole blood four-color flow cytometric assay.

  2008cited by this paper
• Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth

  2008cited by this paper
• Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis

  2008cited by this paper
• Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

  2008cited by this paper
• Circulating endothelial cells in oncology: pitfalls and promises

  2008cited by this paper
• Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

  2008cited by this paper
• A catalytic role for proangiogenic marrow-derived cells in tumor neovascularization.

  2008cited by this paper
• A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors

  2008cited by this paper
• HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.

  2008cited by this paper
• Les cellules endothéliales circulantes : biomarqueurs d’activité des thérapies anti-angiogéniques

  2007cited by this paper
• Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.

  2007cited by this paper
• [Circulating endothelial cells: biomarkers for monitoring activity of antiangiogenic therapy].

  2007cited by this paper
• Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization.

  2007cited by this paper
• Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel

  2007cited by this paper
• Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer

  2007cited by this paper
• Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.

  2007cited by this paper
• Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors

  2006cited by this paper
• Current development status of small-molecule vascular disrupting agents.

  2006cited by this paper
• Macrophages: obligate partners for tumor cell migration, invasion, and metastasis.

  2006cited by this paper
• The multifaceted circulating endothelial cell in cancer: towards marker and target identification

  2006cited by this paper
• Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.

  2006cited by this paper
• Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.

  2006cited by this paper
• Tumour vascular targeting

  2005cited by this paper
• IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A

  2005cited by this paper
• Vascular targeting therapies for treatment of malignant disease

  2005cited by this paper
• Repopulation of cancer cells during therapy: an important cause of treatment failure

  2005cited by this paper
• Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

  2005cited by this paper
• Tie2 identifies a hematopoietic monocytes required for tumor lineage of proangiogenic vessel formation and a mesenchymal population of pericyte progenitors

  2005cited by this paper
• Disrupting tumour blood vessels

  2005cited by this paper
• Circulating endothelial cells

  2005cited by this paper
• Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium.

  2004cited by this paper
• Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.

  2004cited by this paper
• Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.

  2004cited by this paper
• Vascular‐targeting therapies for treatment of malignant disease

  2004cited by this paper
• Utilization of Bone Marrow-Derived Endothelial Cell Precursors in Spontaneous Prostate Tumors Varies with Tumor Grade

  2004cited by this paper
• Endothelial progenitor cells: past, state of the art, and future

  2004cited by this paper
• Circulating Endothelial Cells: Realities and Promises in Vascular Disorders

  2003cited by this paper
• Role of bone marrow-derived cells in tumor angiogenesis and treatment.

  2003cited by this paper
• Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors.

  2003cited by this paper
• Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells

  2003cited by this paper
• Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors

  2002cited by this paper
• Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand.

  2002cited by this paper
• Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

  2001cited by this paper
• Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.

  2001cited by this paper
• Mobilization of Endothelial Progenitor Cells in Patients With Acute Myocardial Infarction

  2001cited by this paper
• Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.

  2000cited by this paper
• Circulating endothelial cells in vascular disorders: new insights into an old concept

  2000cited by this paper
• VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease.

  2000cited by this paper
• Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

  1999cited by this paper
• Isolation of Putative Progenitor Endothelial Cells for Angiogenesis

  1997cited by this paper
• Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.

  1997cited by this paper
• Cancer Research

  1902cited by this paper

• Vascular Disruption Therapy as a New Strategy for Cancer Treatment

  2025cites this paper
• New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.

  2022cites this paper
• Perivascular cell‐derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs

  2021influential citation
• Angiogenesis as a hallmark of solid tumors - clinical perspectives

  2021cites this paper
• DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns.

  2020cites this paper
• Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer

  2020cites this paper
• Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma

  2020cites this paper
• Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft lung cancer mouse model

  2019cites this paper
• Effect of Vascular Disrupting Agent (CA-4DP) and Ionizing Radiation on Tumor Growth in Rats

  2019cites this paper
• Bacterial particles retard tumor growth as a novel vascular disrupting agent.

  2019cites this paper
• The pro-tumorigenic host response to cancer therapies

  2019cites this paper
• Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers

  2018cites this paper
• Mechanisms of Anti-Angiogenic Therapy

  2017cites this paper
• The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells

  2017cites this paper
• Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.

  2017cites this paper
• The antiangiogenic role of the pro-inflammatory cytokine interleukin-31

  2017cites this paper
• Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model

  2016cites this paper
• Targeting vasculogenesis to prevent progression in multiple myeloma

  2016cites this paper
• Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

  2016influential citation
• Significance and therapeutic implications of endothelial progenitor cells in angiogenic-mediated tumour metastasis.

  2016cites this paper
• Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects

  2016cites this paper
• Role of the tumor stroma in resistance to anti-angiogenic therapy.

  2016cites this paper
• Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors.

  2016cites this paper
• May the remodeling of the Ca²⁺ toolkit in endothelial progenitor cells derived from cancer patients suggest alternative targets for anti-angiogenic treatment?

  2015cites this paper
• Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors.

  2015cites this paper
• Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo

  2015cites this paper
• Endothelial progenitor cells support tumour growth and metastatisation: implications for the resistance to anti-angiogenic therapy

  2015cites this paper
• Targeting endothelial progenitor cells in cancer as a novel biomarker and anti-angiogenic therapy.

  2015cites this paper
• Progenitor Endothelial Cells as Biomarkers of Anti-vascular Agents

  2014cites this paper
• Angiogenesis in Spontaneous Tumors and Implications for Comparative Tumor Biology

  2014cites this paper
• Role of endothelial progenitor cells in cancer progression.

  2014cites this paper
• In vivo bio-distribution and homing of endothelial outgrowth cells in a tumour model.

  2014cites this paper
• Prodrug Strategies for Targeting Tumour Hypoxia

  2014cites this paper
• Treatment with a vascular disrupting agent does not increase recruitment of indium labelled human endothelial outgrowth cells in an experimental tumour model

  2014influential citation
• A Combretastatin-Mediated Decrease in Neutrophil Concentration in Peripheral Blood and the Impact on the Anti-Tumor Activity of This Drug in Two Different Murine Tumor Models

  2014cites this paper
• An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

  2014cites this paper
• Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies

  2014cites this paper
• In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.

  2014cites this paper
• Mechanisms of resistance to anti-angiogenesis therapies.

  2013cites this paper
• Understanding and targeting resistance to anti-angiogenic therapies.

  2013cites this paper
• relevance to chemoresistance derived cells in mice: - Notch1 regulates angio-supportive bone marrow

  2013cites this paper
• Blood Outgrowth Endothelial Cells Increase Tumor Growth Rates and Modify Tumor Physiology: Relevance for Therapeutic Targeting

  2013cites this paper
• Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.

  2013cites this paper
• Targeting Bone Marrow Small Non-coding RNAs in Cancer

  2013cites this paper
• Modélisation théorique du développement tumoral sous fenêtre dorsale : Vers un outil clinique d'individualisation et d'optimisation de la thérapie

  2013cites this paper
• NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells

  2013influential citation
• Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

  2013cites this paper
• Notch1 regulates angio-supportive bone marrow-derived cells in mice: relevance to chemoresistance.

  2013cites this paper
• Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.

  2012cites this paper
• Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer

  2012cites this paper
• Circulating endothelial progenitors and tumor resistance to vascular-targeting therapies.

  2012cites this paper